Ketamine treatment represents a groundbreaking advancement in mental health care, offering a new pathway towards mental wellness and improved quality of life with minimal risk of adverse effects. Ketamine effectively assists individuals unresponsive to conventional treatments (Griffiths et al., 2021). Its effectiveness in treating various mental health conditions, including chronic PTSD (Feder et al., 2014, 2021), treatment-resistant depression (Feifel et al., 2017), and substance use disorders (Jones et al., 2018), has been extensively documented. Ketamine’s rapid onset of action is remarkable, with some people experiencing mood improvements within a mere 24 hours (Feifel et al., 2017). Repeated ketamine administrations lead to cumulative antidepressant effects, ensuring sustained improvement over time (Phillips et al., 2019). Ketamine’s therapeutic benefit stems from its modulation of N-methyl-D-aspartate receptors within the brain’s glutamatergic system. By fostering neural plasticity and connectivity, ketamine can recalibrate the neural networks disrupted in mood disorders such as depression, resulting in rapid improvements in mood and cognitive functions (Xu et al., 2022)..

Ketamine found effective in treating severe depression

May 31, 20230

In a clinical trial of 403 patients, Massachusetts General Brigham investigators found that 55 percent of those who received ketamine treatment experienced a sustained improvement in depressive symptoms without major side effects.

The new MGB-led study compared subanesthetic intravenous ketamine to electroconvulsive therapy (ECT) for the treatment of non-psychotic, treatment-resistant depression. The results are published in the New England Journal of Medicine.

Leave a Reply

Your email address will not be published. Required fields are marked *